SMO and neoplasm: Taken together, despite the positive results observed for some of these SHH inhibitors in clinical trials in the context of other tumor types, some patients presented resistance to this strategy (e.g., SHH medulloblastoma patients developed a point mutation in SMO upon treatment, disrupting the ability of sonidegib or vismodegib to bind to SMO [162]).